Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roivant Splashes Cash Again To License GSK Skin Disorder Drug

Executive Summary

The UK drug maker is tightening its R&D focus by selling on the psoriasis and atopic dermatitis investigational drug tapinarof to Dermavant, banking a hefty £150m up front and possibly another £100m after that.

You may also be interested in...



Dermavant Prepares For First Launch, Looking To Build A Blockbuster Psoriasis Brand

The Roivant-owned company's Vtama topical cream was approved by the US FDA with a broad label permitting use for mild, moderate or severe psoriasis.

Dermavant's Tapinarof Could Bring Innovation To Topical Psoriasis Market

CEO Todd Zavodnick said the non-steroidal topical cream is poised to become a blockbuster brand.

Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs

Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC123414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel